Business Context and Reporting Period
This Form 8-K Current Report was filed by Akebia Therapeutics, Inc. on January 8, 2024. The filing reports the appointment of a new executive officer effective January 8, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Richard C. Malabre as Chief Accounting Officer and principal accounting officer. He reports directly to Ellen Snow, the Senior Vice President, Chief Financial Officer, Treasurer, and principal financial officer.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for Mr. Malabre under an at-will employment offer letter:
- Base Salary: $380,000 per year.
- Cash Bonus: Performance-based annual target of up to 35% of base salary.
- Equity Grants (Effective January 31, 2024):
- 336,000 stock options with an exercise price equal to the closing price on the grant date. Vesting occurs over four years (25% on the first anniversary, remaining 75% in equal quarterly installments).
- 223,950 restricted stock units (RSUs) under the 2023 Stock Incentive Plan. Vesting occurs over three years (one-third on each anniversary).
- Additional Agreements: The Company will enter into an Indemnification Agreement and an Executive Severance Agreement consistent with forms described in the April 28, 2023 proxy statement.
The filing does not contain forward-looking guidance, risk factors, or contingencies beyond standard executive appointment disclosures.
Investor Verification Checklist
- Verify the vesting schedules and exercise prices for the 336,000 options and 223,950 RSUs granted to Mr. Malabre.
- Review the specific terms of the Executive Severance Agreement expected to be filed as an exhibit to the 2023 Form 10-K.
- Confirm the impact of this appointment on the Company's stock-based compensation expense in future periods.